Mizuho Reaffirms Evolus (EOLS) As “Buy”; Has Target Price Of $33; Morgan Stanley Emerging Markets Debt Fund (MSD)’s Sentiment Is 2.3

June 16, 2018 - By Matthew Harris

Evolus (EOLS) had its stock rating noted as “Buy” by analysts at Mizuho. Mizuho currently has a $33 target price on the $669.50 million market cap company or 16.53% upside potential. This was disclosed to clients in a research note on Monday, 11 June.

Morgan Stanley Emerging Markets Debt Fund Inc (MSD) investors sentiment increased to 2.3 in 2018 Q1. It’s up 1.05, from 1.25 in 2017Q4. The ratio has improved, as 23 investment managers opened new and increased positions, while 10 cut down and sold stakes in Morgan Stanley Emerging Markets Debt Fund Inc. The investment managers in our database reported: 6.00 million shares, up from 5.61 million shares in 2017Q4. Also, the number of investment managers holding Morgan Stanley Emerging Markets Debt Fund Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 5 Increased: 11 New Position: 12.

Analysts await Evolus, Inc. (NASDAQ:EOLS) to report earnings on August, 9. After $-0.30 actual earnings per share reported by Evolus, Inc. for the previous quarter, Wall Street now forecasts 23.33% negative EPS growth.

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. The company has market cap of $669.50 million. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. It currently has negative earnings.

Among 2 analysts covering Evolus Inc (EOLS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evolus Inc has $35 highest and $1600 lowest target. $34’s average target is 20.06% above currents $28.32 stock price. Evolus Inc had 11 analyst reports since March 5, 2018 according to SRatingsIntel. The company was maintained on Wednesday, May 16 by Mizuho. The firm has “Buy” rating by Mizuho given on Monday, June 11. Mizuho maintained it with “Buy” rating and $2100 target in Thursday, April 19 report. On Tuesday, April 3 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 7. The rating was maintained by Cantor Fitzgerald with “Overweight” on Wednesday, June 13. The stock of Evolus, Inc. (NASDAQ:EOLS) earned “Buy” rating by Mizuho on Monday, March 5. The company was initiated on Monday, March 5 by Cantor Fitzgerald. Mizuho maintained Evolus, Inc. (NASDAQ:EOLS) rating on Monday, May 7. Mizuho has “Buy” rating and $2100 target. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, April 12 report.

The stock decreased 1.84% or $0.53 during the last trading session, reaching $28.32. About 292,012 shares traded. Evolus, Inc. (EOLS) has 0.00% since June 16, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical EOLS News: 16/05/2018 – Evolus Presenting at Bank of America Conference Tomorrow; 07/05/2018 – Evolus: Moatazedi Succeeding Murthy Simhambhatla; 04/05/2018 – DJ Evolus Inc, Inst Holders, 1Q 2018 (EOLS); 16/05/2018 – Evolus investors frown as FDA declines to approve Botox rival; 16/05/2018 – EVOLUS INC – EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS; 16/05/2018 – FDA declines to approve Evolus’ rival treatment to Botox; 16/05/2018 – EVOLUS INC – FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY; 16/05/2018 – Evolus Announces Progress with DWP-450 Regulatory Submissions; 16/05/2018 – EVOLUS INC – DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND; 15/05/2018 – Anybody hear anything on $EOLS? Mighty quiet

More notable recent Evolus, Inc. (NASDAQ:EOLS) news were published by: Globenewswire.com which released: “Evolus to Participate in Two Upcoming Investor Conferences” on June 14, 2018, also Seekingalpha.com with their article: “Profit-taking pressures Evolus, down 18%” published on June 08, 2018, Globenewswire.com published: “Evolus to Present at the Jefferies 2018 Global Healthcare Conference” on June 04, 2018. More interesting news about Evolus, Inc. (NASDAQ:EOLS) were released by: Seekingalpha.com and their article: “Buy Lockheed Martin On Weakness – Cramer’s Lightning Round (6/14/18)” published on June 15, 2018 as well as Ocbj.com‘s news article titled: “Midday Stock Roundup” with publication date: June 13, 2018.

Evolus, Inc. (NASDAQ:EOLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: